Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Survival Study in Patients Undergoing On-Line Hemodiafiltration (ESHOL)
This study is currently recruiting participants.
Verified by Hospital Clinic of Barcelona, June 2008
Sponsors and Collaborators: Hospital Clinic of Barcelona
Societat Catalana de Nefrologia
Information provided by: Hospital Clinic of Barcelona
ClinicalTrials.gov Identifier: NCT00694031
  Purpose

Patients on hemodialysis will be randomly assigned (1:1) to continue on conventional hemodialysis or on-line hemodiafiltration, both three times per week. A 3 year follow-up and a sample size of around 750 will be necessary to detect a 35% reduction in mortality.


Condition Intervention Phase
Hemodialysis
Procedure: Hemodialysis
Procedure: On-line hemodiafiltration
Phase IV

MedlinePlus related topics: Dialysis Kidney Failure
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Official Title: A Randomized Study to Evaluate Survival in Patients Undergoing Hemodialysis or On-Line Hemodiafiltration

Further study details as provided by Hospital Clinic of Barcelona:

Primary Outcome Measures:
  • Survival [ Time Frame: 36 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 800
Study Start Date: May 2007
Estimated Study Completion Date: June 2011
Estimated Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
A: Active Comparator
Hemodialysis
Procedure: Hemodialysis
3 times per week
B: Experimental
On-line hemodiafiltration
Procedure: On-line hemodiafiltration
3 times per week

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18 and older
  • Currently undergoing hemodialysis
  • Clinical stability
  • Stable vascular access

Exclusion Criteria:

  • Chronic inflammatory diseases
  • Liver cirrhosis
  • Malignancies
  • Chronic immunosuppressant or antiinflammatory use
  • Dialysis through temporary catheter or single puncture
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00694031

Contacts
Contact: Francesc Maduell, MD 34-9-3227-5400 fmaduell@clinic.ub.es

Locations
Spain
Hospital Clinic de Barcelona Recruiting
Barcelona, Spain, 08036
Contact: Francesc Maduell, MD     34-9-3227-5400     fmaduell@clinic.ub.es    
Spain, Barcelona
CSU Bellvitge Recruiting
Hospitalet de Llobregat, Barcelona, Spain, 08907
Principal Investigator: Albert Martinez-Castelao, MD            
Sponsors and Collaborators
Hospital Clinic of Barcelona
Societat Catalana de Nefrologia
  More Information

Responsible Party: Hospital Clínic ( Francesc Maduell )
Study ID Numbers: ESHOL
Study First Received: June 5, 2008
Last Updated: June 9, 2008
ClinicalTrials.gov Identifier: NCT00694031  
Health Authority: Spain: Spanish Agency of Medicines

Keywords provided by Hospital Clinic of Barcelona:
Mortality
Convective therapies
On-line Hemodiafiltration
Dialysis Adequacy
Age 18 or older
Undergoing hemodialysis

ClinicalTrials.gov processed this record on January 16, 2009